parusahaan biotéhnologi Britania MiNA Therapeutics ‘innovative RNA therapy may enhance liver cancer patients’ response to standard treatment. The therapy uses a double-stranded RNA that can activate a target gene called CEBPA. Packaging double-stranded RNA in lipid nanoparticles helps to penetrate into liver cells that are often difficult to reach and can control gene expression in the nucleus. It is understood that the low level expression of certain genes is related to liver kangker and other liver diseases. In laboratory studies, increasing the expression of CEBPA to restore its protein levels to normal can help reduce the growth of cancer cells.
Diantara pasien anu nampi RNA aktif biotéhnologis leutik (saRNA), dua di antarana nunjukkeun réspon lengkep saatos nampi sorafenib, sareng anu sanésna nunjukkeun réspon parsial saatos perawatan sareng lenvatinib. Ieu mangrupikeun uji coba terapi saRNA munggaran pikeun manusa. Kusabab panilitian masih dina tahap awal, perusahaan biotéh ayeuna ngarep-arep ngumpulkeun bukti anu langkung relevan.
Pausahaan ogé ngaharepkeun pikeun ngalaksanakeun tés ubar anu sami dina penderita sirosis di hareup, sareng ogé gawé bareng sareng Boehringer Ingelheim pikeun ngalaksanakeun proyék-proyék sanés pikeun panyakit ati. Saatos pamekaran anu lami, langkung seueur pangobatan RNA parantos asup ka pasar. Beda sareng terapi MiNA anu ngaktifkeun éksprési gén, seuseueurna ngagunakeun téknologi interferensi RNA (RNAi) pikeun ngirangan éksprési gén. Anyar, Komisi Éropa disatujuan Onpattro, ubar RNAi munggaran dikembangkeun ku Alnylam pikeun pengobatan polyneuropathy.
